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Glomerular matrix accumulation is linked to inhibition of the
plasmin protease system
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Glomerular matrix accumulation is linked to inhibition of the plasmin
protease system. TGF-f plays a pivotal role in the pathological accu-
mulation of extracellular matrix in experimental glomerulonephritis.
Increased TGF-/3 expression leads to increased synthesis and deposi-
tion of extracellular matrix components while administration of anti-
serum to TGF-/3 suppresses the major manifestations of the disease. We
hypothesized that TGF-/3 might also enhance matrix accumulation by
decreasing matrix turnover via effects on protease/protease inhibitor
balance. Plasmin is a potent protease capable of degrading a variety of
matrix molecules. Plasmin generation from plasminogen is regulated by
plasminogen activator(s) (PA) and plasminogen activator inhibitor(s)(PAT). In this study PA activity was markedly reduced and PAI-l
synthesis dramatically increased when TGF-13 was added to normal
glomeruli. Diseased glomeruli also showed decreased PA activity,
increased PAl-i synthesis and increased PAI-l deposition into matrix.
Administration of anti-TGF- serum to glomerulonephritic rats blocked
the expected increase in glomerular PAT-i deposition. Thus changes in
the PA/PA! balance favoring accumulation of matrix are induced by
TGF-/3 in normal glomeruli and are present in nephritic glomeruli when
endogenous TGF-/3 production is high. Our findings implicate the
plasmin protease system in tissue repair following acute glomerular
injury and suggest another mechanism by which TGF-$ enhances the
matrix accumulation characteristic of many glomerular diseases.
A central feature of progressive glomerular disease, whether
due to glomerulonephritis or diabetes, is accumulation of extra-
cellular matrix leading to the development of glomerulosclero-
sis [1, 2]. In acute mesangial proliferative glomerulonephritis
induced in rats by the administration of anti-thymocyte serum
(ATS), we have shown that immunological injury induces
elevated glomerular expression of transforming growth factor-a
(TGF-/3) mRNA and TGF-/3 protein. The expression of TGF-13
in the glomerulus is followed closely by induction of synthesis
of two chondroitin/dermatan sulfate proteoglycans, decorin and
biglycan, which are considered markers of TGF-/3 activity [3],
and a major matrix glycoprotein, fibronectin. Further demon-
stration of the causal role of TGF-/ in this model is that
administration of a neutralizing antibody to TGF-/3 suppresses
glomerular accumulation of extracellular matrix [4]. Other work
in an experimental model of rapidly progressive glomerulone-
phritis induced by administration of anti-glomerular basement
membrane antibody, has also shown a close correlation be-
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tween expression of TGF-/3 and the development of renal
fibrosis [5].
TGF-/3 is a growth factor unique in its widespread effects on
extracellular matrix [6]. From in vitro experiments using a
number of cell lines, TGF-p has been shown to: (1) increase the
production of matrix glycoproteins and proteoglycans [7—13];
(2) modulate the expression of some integrin-type receptors on
cells in a manner that might lead to increased cell adhesion to
matrix [14, 15]; (3) decrease the production of matrix degrading
proteases [16—18]; and (4) increase the level of protease inhib-
itors [15—19]. Modulation of the balance between proteases and
their inhibitors is one potentially important mechanism by
which TGF-f3 enhances accumulation of extracellular matrix
following tissue injury.
One of the protease cascades strongly influenced by TGF-/3 is
plasminogen activator (PA)/plasmin system. Plasmin is a potent
serine protease best known for its activity against fibrin, but
plasmin is also capable of degrading extracellular matrix and
probably plays an important role in the proteolysis that accom-
panies tissue repair [20, 21]. Plasmin generation from plasmin-
ogen is regulated by the interaction of activators and inhibitors.
There are two distinct types of plasminogen activators (PA) that
convert the zymogen plasminogen to plasmin, tissue-type (t-
PA) and urokinase-type (u-PA). u-PA has been implicated in a
variety of extravascular processes including tissue remodeling
and cell migration. The PAs are counterbalanced by inhibitors
of which plasminogen activator inhibitor-i (PAl-i) is one of the
most important.
In our previous work using the ATS model of glomerulone-
phritis we showed a close correlation between expression of
TGF-/3 and mesangial matrix expansion. Other investigators
have shown a role for PDGF in mesangial cell proliferation in
this model of glomerulonephritis [22]. Both of these cytokines
induce high levels of PAl-i in many cell lines [16, 17, 23—25]. A
recent study showed dramatic accumulation of PAl-i mRNA in
mouse kidney three hours after injection of purified human
recombinant TGF-/31 [26]. Although these cytokines induce
large changes in PAl-I synthesis, the in vivo significance of
these actions is unknown. In addition to the strong induction of
matrix synthesis by TGF-f3 and the mesangial cell proliferation
brought about by PDGF, we questioned whether effects on
protease/protease inhibitor balance might contribute to the
accumulation of pathologic matrix. In the current study, we
report that TGF-f3 markedly stimulates active PAI-l synthesis
by normal glomeruli. Furthermore, nephritic glomeruli show
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decreased PA activity and increased PAl-i synthesis which
precede the accumulation of extracellular matrix in the ne-
phritic glomeruli. Returns to normal PAl-I synthesis and PA
activity precede resolution of accumulated matrix during recov-
ery from disease, results consistent with the hypothesis that the
PA/PAl-i protease system plays a role in matrix accumulation
during disease and possibly matrix degradation during recov-
ery. Finally, a significantly increased deposition of PAl- 1 in
nephritic glomeruli is largely prevented by in vivo administra-
tion of neutralizing antibodies to TGF-/3, indicating a causal role
for TGF-13 in the increased glomerular deposition of PAI-l in
disease.
Methods
Animals
Four- to six-week-old Sprague-Dawley rats from Sasco, Inc.
(Omaha, Nebraska, USA) and four-month-old New Zealand
white rabbits from Ellis and Prichard (American Fork, Utah,
USA) were maintained in specific pathogen-free conditions and
used in all experiments.
Growth factors, antibodies and reagents
Porcine platelet TGF-f3l was from R&D Systems (Minneap-
olis, Minnesota, USA). PDGF-BB was from Boehringer Mann-
heim (Indianapolis, Indiana, USA). Rabbit anti-rat PAl-I IgG
was obtained from American Diagnostica (New York, New
York, USA). Biotin was from Calbiochem (San Diego, Califor-
nia, USA); avidin-FITC and biotin blocking reagents were from
Pierce (Rockford, Illinois, USA).
Sieves for glomerular isolation and tissue culture plastic ware
were from Baxter Scientific (Salt Lake City, Utah, USA).
Tissue culture supplies included RPM! 1640 culture medium
and HEPES buffer solution from Irvine Scientific (Irvine,
California, USA), methionine- and glutamine-free RPM!, peni-
cillin and streptomycin from ICN Flow Laboratories (Costa
Mesa, California, USA) and fetal calf serum (FCS) from Hy-
clone (Logan, Utah, USA). Reagents to measure PA activity,
including plasminogen, low molecular weight human u-PA and
H-D-Val-Leu-Lys-p-nitroanilide (S-225l) were from KabiVit-
rum (Franklin, Ohio, USA). Electrophoresis supplies were
from Bio-Rad (Richmond, California, USA). Precast polyacryl-
amide gels (4 to 12% gradient) were obtained from NOVEX
(Encinitas, California, USA).
35S-methionine (EXPRE35S35S-protein labeling mix) and EN-
LIGHTNING came from New England Nuclear Dupont (Bos-
ton, Massachusetts, USA). Ketamine-HC1 from Aveco (Fort
Dodge, Iowa, USA) and xylazine from Miles Laboratories
(Shawnee, Kansas, USA) were used for anesthesia. X-ray films
were from Eastman Kodak (Rochester, New York, USA).
Staphylococcal protein-A-Sepharose CL4B and all other re-
agents not specifically mentioned were from Sigma Chemical
Company (St. Louis, Missouri, USA).
Induction of experimental glomerulonephritis
Anti-thymocyte serum (ATS) was produced in New Zealand
white rabbits and glomerulonephritis was induced in Sprague-
Dawley rats by intravenous administration of 1 ml of ATS as
previously described [3]. The day of injection was designated as
day 0. Rats were killed 3, 7, and 14 days after ATS administra-
tion for histologic examination of kidney tissue and isolation of
glomeruli for culture.
Glomerular culture
Rats were anesthetized intramuscularly with ketamine HC1,
and xylazine (10 mg, and 0.5 mg per 100 g body wt, respective-
ly). The kidneys were perfused in situ via the aorta with PBS
pH 7.4 and excised. The capsules were removed and the
cortical tissue was dissected out and minced with a razor blade.
Glomeruli were isolated using the graded sieving technique [3].
Isolated glomeruli were washed three times in PBS and resus-
pended at 1.5 x iO glomeruli per ml in methionine-, serum- and
antibiotic-free RPMI-1640 in six well plates. After two hours of
incubation with various concentrations of TGF-J3 the cultures
were biosynthetically labeled by addition of 50 CiIml 355
methionine for an additional 24 hours. Phenylmethyl-sulfonyl
fluoride (PMSF) was added to a final concentration of 1 m.
Samples were centrifuged to remove glomeruli and culture
supernatants were frozen at —20°C until use. Where samples
were to be assayed for PA activity, radiolabel and PMSF were
omitted.
Electrophoretic technique
Samples for SDS-PAGE were mixed with sample buffer [27]
containing 3% sodium dodecyl sulfate (SDS) and 10% 2-mer-
captoethanol, and were heated for five minutes at 100°C.
Twenty microliter aliquots were applied to 4 to 12% gradient
gels, and gels were run for three hours at constant power. For
autofluorography, gels were incubated in ENLIGHTENING
for one hour, dried and exposed to x-ray film, typically for a one
to two day exposure. Autofluorograms were scanned with an
Ultrascan XL Enhanced Laser Densitometer (Pharmacia, Upp-
sala, Sweden) to compare and quantitate the relative intensities
of the protein bands. Autofluorograms exposed for different
time periods were scanned to check the linearity of densitom-
eter readings.
Plasminogen activator (PA) assay
PA activity was assayed by measuring the hydrolysis of
synthetic substrate by formed piasmin in the presence of
plasminogen [28]. Assays were performed in polyvinyl chloride
microtiter plates. The total volume of 125 1d was comprised of
the following: sample, H-D-Val-Leu-Lys-p-nitroanilide (0.01
sM), and plasminogen (0.03 M) in 0.5% Triton X-l00, 0.1 M
Tris, pH 8.0. The amount of p-nitroaniline released was mea-
sured at 410 nm with a Dynatech MR700 microplate reader
(Dynatech Laboratories, Alexandria, Virginia, USA). A stan-
dard curve was generated with each assay using low molecular
weight human u-PA. Each sample was also assayed without
plasminogen to establish the plasminogen-dependence of the
enzyme activity. The PA activity in culture supernatant or cell
lysate was expressed as IU/1000 glomeruli. Where indicated
amiloride (1 mM), an inhibitor of u-PA but not t-PA [29], was
included in the assay mixture.
Substrate gel electrophoresis (zymography)
The method of Granelli-Piperno and Reich [30] was modified
as follows: plasminogen (0.03 /LM) and a-casein (0.2 mg/mi)
were added to a 12.5% polyacrylamide gel mixture prior to
casting. Samples were not boiled or reduced prior to the
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analysis. After electrophoresis the gel was soaked for one hour
in 2.5% Triton X-l00 and then overnight in 0.1 M glycine buffer,
pH 8.0 at 37°C. Clear a-casein zones of lysis were localized by
staining the gel with Coomassie Blue. The samples were also
run on gels without plasminogen to establish that the zones of
lysis were attributable to PA.
Immunoprecipitation
Samples (1 ml) were preabsorbed with 50 .d rabbit serum and
100 d 50% (vollvol) Protein-A Sepharose CL-4B at 4°C for two
hours. After centrifugation the media were collected and 5 g of
anti-PAl-i IgG in 100 .d distilled water was added together with
50 d protein-A Sepharose. The samples were then incubated in
a rotary shaker at 4°C for 16 hours. The antigen-antibody
complexes bound to Protein-A Sepharose were collected by
centrifugation, washed three times with 10 mt Tris-HC1 buffer,
pH 7.5, containing 0.5% Triton X, 0.1% SDS, and 0.5% sodium
deoxycholate, and once with PBS. The precipitated proteins
were dissolved in Laemmli's sample buffer, boiled for five
minutes and analyzed by SDS-PAGE as described above. When
appropriate decreasing quantities of media were used to ensure
that immunoprecipitation was quantitative.
Immunofluorescent staining
Kidneys were perfused via the aorta with cold PBS, isolated
and minced. The mince was snap-frozen in 2-methylbutane that
had been cooled in liquid nitrogen. Three to five micrometer
sections were obtained using a cryostat (Tissue-Tek-lI, Miles
Laboratories, Elkhart, Indiana, USA). The tissue was air dried
and infixed. After blocking with biotin and avidin, sections were
stained with 2.5 g anti-PAl- 1 IgG which had been biotinylated
by the method of Berman and Basch [31]. Avidin-FITC was
then applied and immunofluorescence was examined using an
epifluorescence microscope (Zeiss, Germany).
Effect of in vivo administration of TGF-/3 antiserum and
immunohistological staining
Paraffin fixed tissues were examined from an earlier study
where anti-TGF-f31 was given at the time of induction of
glomerular disease and was shown to suppress the increased
production and accumulation of extracellular matrix [4].
Briefly, anti-TGF-f3 serum or one of two control rabbit sera
were injected for six consecutive days starting with the day
anti-thymocyte serum was given. Normal control and disease
control animals were injected with normal rabbit serum (NRS)
instead of anti-TGF-f3 serum. On days 7 and 14 after induction
of disease, kidneys were isolated, fixed in 10% neutralized
formalin and paraffin embedded. One micrometer sections were
mounted on poly-L-lysine coated slides, deparaffinized and
exposed to 0.3% hydrogen peroxide for 30 minutes. Immuno-
histochemical staining with rabbit anti-rat PAl-i was detected
with biotinylated goat anti-rabbit IgG, followed by avidin-peroxi-
dase (ABC kit, Vector Laboratories). Each incubation was
followed with a five minute wash with PBS. Staining was
visualized with 0.05% 3,3 '-diaminobenzedene/0.03% hydrogen
peroxide in PBS. Immunoperoxidase staining was quantitated
in a blinded fashion by scoring distribution and intensity of
glomerular staining on a scale of 1 to 4 in at least 20 glomeruli
from three rats in each group. All slides were stained simulta-
Fig. 1. Effects of PDGF and TGF-13 on normal glomeruli. Equal
numbers of normal rat glomeruli were exposed to either PDGF-BB or
TGF-13l for 24 hours in the presence of 35S-methionine. The fluorogram
shown is from SDS-PAGE of 20 d of each culture supernatant. The
position of PAl-i is indicated by an arrow.
neously and photographed using the same light intensity and
exposure time.
Statistical comparisons were done on data from three repli-
cate experiments using t-tests.
Results
Response of normal glomeruli to PDGF and TGF-f31
Normal glomeruli were isolated and incubated with and
without increasing concentrations of PDGF and TGF-J31 in the
presence of 35S-methionine for 24 hours. Aliquots of culture
supernatant were run on PAGE. Fluorograms obtained from a
representative gel are shown in Figure 1. In the presence of
TGF-131 a clear increase in a band at 50 kD is seen, consistent
with the molecular weight of PAI-l. This increase is absent
from glomeruli treated with PDGF-BB. Concentrations of
PDGF-BB as high as 30 nglml showed no increase in this 50 kD
band (data not shown). These data suggest that TGF-/3l but not
PDGF-BB stimulate PAl-i synthesis by normal glomeruli.
The effect of TGF-f3l was examined further by measuring the
PA activity in cultures of normal glomeruli using two methods,
chromogenic substrate assays (Fig. 2A) and substrate gel elec-
trophoresis (Fig. 2B). Both methods showed the presence of PA
activity in normal glomerular cultures and a marked decrease in
PA activity in response to the lowest dose of TGF-f31 tested (1
ng/ml). Substrate gel electrophoresis showed a 50 kD plasmino-
gen-dependent zone of lysis consistent with u-PA. Gels without
added plasminogen showed no 50 kD band in the absence of
TGF-pl (data not shown). That the PA activity was due to u-PA
and not t-PA was suggested by the nearly complete inhibition of
the activity by amiloride (data not shown) [29].
To examine further PAl-i expression in this system, normal
glomeruli were metabolically labeled in the presence of varying
concentrations of TGF-pl. After 24 hours, PAl-i was immuno-
precipitated from culture supernatants. Aliquots of the same
samples precipitated with normal rabbit serum (1:100 dilution)
showed no labeled proteins, confirming the specificity of the
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Fig. 2. Effect of TGF-f31 on PA and PAl-i
production by isolated normal glomeruli.
Equal numbers (1.5 x l0) of normal rat
glomeruli were exposed to increasing
concentrations of TGF-j31 for 24 hours. (A)
PA activity in the medium was analyzed by
chromogenic substrate assay and expressed
per 1000 glomeruli. (B) PA activity analyzed
by substrate gel electrophoresis. With
plasminogen in the gel, conditioned medium
produced a clear lysis zone at 50 kD,
consistent with u-PA activity. In the presence
of TGF-/3, this band was not seen. This band
was absent when plasminogen was omitted
from the gel (data not shown). A 70 kD
plasminogen-independent zone of lysis was
also decreased by TGF-13. (C) Glomeruli were
metabolically labeled with 35S-methionine at
the time of addition of TGF-/3. PAI-l was
immunoprecipitated from 1 ml of labeled
medium and analyzed by SDS-PAGE and
fluorography.
immunoprecipitation (data not shown). The results show that
normal glomeruli spontaneously produce small amounts of
PAl-i. With the addition of low concentrations of TGF-/31
striking increases in PAl-i synthesis are seen (Fig. 2C). Densi-
tometry indicates that the lowest concentration (1 nglml) of
TGF-/31 induces an 8.5 0.70-fold increase over control in
newly synthesized PAI-l in culture supernatant. Higher con-
centrations of added TGF-,91 produce further stimulation of
PAl-i synthesis resulting in a 15.2 1.2-fold increase over
control at 30 ng/ml TGF-/31/ml (Fig. 2C). Compared to normal
control glomeruli, PAI-l immunoprecipitated from culture su-
pernatant was significantly (P < 0.01) greater for all concentra-
tions of TGF-/3l.
To study the time course of PAl-i synthesis induced by
TGF-/31, normal glomeruli were plated into multiple tissue
culture wells containing TGF-/3 (10 nglml), serum-free medium
and 35S-methionine. TGF-f3l was omitted from the control
wells. Culture supernatant was removed from the wells at 6, 12,
24 and 48 hour and immunoprecipitated with antiserum to rat
PAT-i. In the presence of 10 ng/m1TGF-31, PA!-! synthesis and
secretion is considerably greater than without exogenous
TGF-/31 (Fig. 3 A and B). A plot of these data reveals that
without exogenous TGF-/31 PAT-i synthesis and secretion
proceeds at a linear rate for 24 hours of culture. In the presence
of TGF-/31 (10 ng/ml) this rate of appearance of newly synthe-
sized PAl- 1 in the supernatant is 4.1 and 5 times greater than in
the absence of added TGF-/31 in replicate experiments (Fig.
3C).
Nephritic glomeruli—PA activity
Intact glomeruli were isolated from normal and glomerulone-
phritic rats 3, 7 and 14 days after injection of ATS. After 24
hours in culture, supernatants were collected and PA activity
was measured by the chromogenic substrate assay. Figure 4A
shows that normal glomeruli secrete plasminogen-dependent
proteolytic activity consistent with active PA. Inhibition by
amiloride suggests this activity is mostly u-PA (Fig. 4A). On
day 3 of the disease this activity is significantly decreased to 15
3% of control activity (P < 0.001). It returns to control values
(101 7%) by day 7 and shows a significant increase over
controls to 142 12% at day 14 of disease (P < 0.005).
Substrate gel electrophoresis run on culture supernatants
from isolated nephritic glomeruli showed a 50 kD plasminogen-
dependent zone of lysis consistent with u-PA (Fig. 4B). No 50
kD band was seen when plasminogen was omitted from the gel
(data not shown). Changes during disease in the 50 kD zone of
lysis (Fig. 4B) parallel the chromogenic substrate assay data
(Fig. 4A).
The second zone of lysis at approximately 70 kD was also
observed in substrate gels without plasminogen. This protease,
potentially from the serine, cysteine or metalloproteinase fam-
ily, has not been characterized to date.
Nephritic glomeruli—Synthesis of PAl-i
Nephritic and normal glomeruli were isolated and placed in
culture for 24 hours with 355-methionine. Culture supernatants
were then immunoprecipitated with PAl-i antiserum. Nephritic
glomeruli synthesize and secrete large quantities of PAI-l (Fig.
4C), similar to the PAT-i synthesis seen when normal glomeruli
were exposed to TGF-/3 (Fig. 2C). Densitometry reveals signif-
icant increases of 4.8 0.6-fold and 5.4 0.4-fold in PAl-I
synthesis at days 3 and 7 of disease, respectively (P < 0.005).
By day 14 of disease a nonsignificant increase to 1.6 0.4 times
control values is seen.
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Fig. 3. Time course of PAl-I
immunoprecipitated from medium conditioned
by normal glomeruli for 6, 12, 24 and 48
hours with (A) and without (B) 10 ng/ml TGF-
/31. Densitometry of these gels yielded the
data plotted in C. The arrow indicates the
PAl-I band.
Immunofluorescent staining for PAl-i
In Figures 5A, B and C are shown representative fluores-
cence micrographs of PAl-i staining in glomeruli from control,
day 7 and day 14 of disease, respectively, Using this method,
staining appears to be primarily in the mesangial matrix and is
reminiscent of the pattern of fibronectin seen in this disease
model [3, 32]. Compared to control (Fig. 5A), there is a clear
increase in PA!-! staining on day 7 of disease (Fig. 5B) and
further increase on Day 14 (Fig. 5C). The apparent increase in
tubular staining seen in Figure SC was seen in all samples and
therefore likely represents a true increase in PAl-i at day 14 of
disease. These data suggest that the increase in glomerular
Fig. 4. PA and PAl-i production by isolated
nephritic glomeruli. Equal numbers of normal
control or nephritic glomeruli isolated on days
3, 7, or 14 of ATS-induced glomerulonephritis
were placed in culture for 24 hours. (A) PA
activity was analyzed and expressed as in
Figure 1. Open bars represent total PA
activity and dotted bars show PA activity
measured after amiloride treatment. (B)
Substrate gel electrophoresis of glomerular
culture supernatant from nephritic glomeruli.
The 50 kD zone of lysis was present in normal
glomeruli, decreased at day 3 of disease and
increased at day 7 and 14. Gels prepared
without plasminogen showed the 70 kD but
not the 50 kD band of lysis (data not shown).
(C) PAl-i was immunoprecipitated as
described in Figure 2C from medium
conditioned by the nephritic glomeruli.
Control Day3 Day? Day 14
Days
A
500
Days
C 3 7 14
C
C 3 7 14
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Fig. 5. Photomicrograph of immunofluorescence staining of PAl-i in
rat glomeruli. (A) glomerulus of a normal control rat, (B) a nephritic
rat at day 7, and (C) a nephritic rat at day 14 of disease. There is a
marked increase in PAl-i deposition in glomerular matrix on day 7
and a further increase on day 14 of disease. The micrographs were
taken under identical conditions. Magnification x500.
PAl-i synthesis leads to an increase in PAl-i deposition into
extracellular matrix. Note that the PAT-i staining is greatest on
day 14 while giomerular synthesis of PAI-l peaks at day 7 and
is close to normal by day 14.
Immunoperoxidase staining of PAl-I and effect of in vivo
administration of TGF-13 antiserum
The results of immunoperoxidase staining of PAT-i in ne-
phritic glomeruli from normal animals, diseased animals and
diseased animals treated with neutralizing antiserum to TGF-/3
are shown quantitatively in Figure 6. A significant increase in
staining was seen in diseased animals compared to controls at
both days 7 and 14 (P < 0.001), consistent with the immunoflu-
orescence data. When diseased animals were injected with
antibodies to TGF-f3 for six successive days, glomerular stain-
ing was significantly decreased compared to disease control
animals on day 7 (P < 0.001) and on day 14 (P < 0.005; Fig. 6).
These data indicate that TGF-J3 plays a causal role in the
increased glomerular deposition of PAl-i in this disease model.
Discussion
The current study demonstrates that TGF-/3 induces changes
in the PA/PAI-l protease system within glomeruli which poten-
tially reduce or inhibit the involvement of plasmin in matrix
degradation. Small quantities of TGF-f3 markedly decrease PA
activity and increase PAT-i synthesis when added to normal
glomeruli in culture. The increase in PAT-i synthesis is detect-
able as early as six hours after exposure to TGF-f3 and contin-
ues so that by 24 hours PAT-i is a dominant protein being
secreted by glomeruli exposed to TGF-f3.
Using the ATS model of glomerulonephritis, we have shown
previously that expression of TGF-/3 mRNA and TGF-p pro-
tein, as well as synthesis of proteoglycan and fibronectin by
nephritic glomeruli, are increased by day 4 of disease. These
events were followed by mesangial matrix expansion by day 7
which peaked by day 14. We now provide evidence that prior to
matrix accumulation, nephritic glomeruli also show striking
changes in the PA/PAI-l system which would favor matrix
accumulation. These changes are similar to those seen when
normal glomeruli are exposed to exogenous TGF-f3l. PA activ-
ity dramatically decreases and PAl-i synthesis increases by day
3 of disease and returns toward control levels by day 7. The
increased synthetic rate of PAl-i is reflected in significantly
elevated PAT-i deposition into glomerular extracellular matrix
on days 7 and 14 of disease. While there is considerable
evidence that secreted PAl-i is rapidly converted to a latent
conformation, binding of PAl-i to matrix appears to stabilize
the active conformation [331. These data indicate that the
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Fig. 6. Quantitation of immunoperoxidase
staining with rabbit anti-rat-PAl-i. Anti-TGF-
/3 significantly blocked PAl- 1 deposition in the
injured glomeruli on both days 7 and 14 of
disease. Mean and standard error of values
from three rats in each group are shown.
< 0.005, diseased rats given control serum
(CS) compared to normal rats; < 0.0001,
diseased rats given control serum (CS)
compared to diseased animals given anti-TGF-
/3 serum (a-T).
components necessary for blocking matrix degradation by
plasmin are in place at an early time point in the disease, prior
to histologic evidence of matrix accumulation. A causal role for
TGF-13 in induction of these changes in the PAl-i/PA protease
system was confirmed by the demonstration that in vivo admin-
istration of anti-TGF-f3 largely blocks the disease-induced in-
crease in glomerular PAl- 1 deposition.
In glomerulonephritis induced by ATS there is evidence that
platelets rapidly aggregate in areas of mesangial injury. This
could result in release of active TGF-/31 and PDGF. TGF-f31 is
capable of inducing its own expression as well as that of PDGF
[34]. PDGF is known to play a role in mesangial cell prolifera-
tion in this disease model. PDGF along with IL-l and TNF-a
have been shown to induce PAI-l expression in other cell lines
[25]. The data presented in Figure 1 suggest that PDGF does not
increase PAl-i synthesis in normal glomeruli whereas TGF-/3l
does. Although we cannot be sure that TGF-/3 alone is respon-
sible for the changes we see with disease in the activity and
expression of PAI-l, several lines of evidence suggest that
TGF-p is a dominant factor: (1) TGF-/31, when added to normal
glomeruli produces changes in the PAJPAI-i balance similar to
those seen in nephritic glomeruli that are secreting increased
levels of active TGF-j3. (2) PDGF had no visible effect on total
protein synthesis or the 50 kD band when added to normal
glomeruli. (3) Anti-TGF-J3 largely blocks deposition of PAI-l
into matrix and, as we have shown previously, suppresses
proteoglycan synthesis and matrix accumulation in this model.
An interesting question is how matrix accumulation is re-
versed during resolution of experimental glomerulonephritis.
Our finding that PA activity at day 14 of disease rebounds to 1.4
times normal, when PA!-! synthesis is not significantly different
from normal, is intriguing. This activity is likely to represent
newly synthesized PA released into the medium and there is
evidence suggesting that PAI-l can be removed from matrix by
binding to PA [33]. Furthermore, recent evidence indicates that
binding of PAl- 1 to cell surface receptor-bound u-PA provides
a signal for internalization and lysosomal degradation of the
u-PA-PAI-l complex [35]. Thus increased production of PA
may lead to increased plasmin generation directly and may also
be part of a mechanism for removal and degradation of PAl- 1
from the extracellular matrix. The effect would be a reversal of
the PA-PAI-l balance toward matrix degradation.
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